Lionel Richie is reportedly recovering after undergoing an atrial fibrillation (Afib) ablation this week, following an episode of dizziness onstage in June and subsequent cardiac testing. The 77-year-old singer's procedure has drawn renewed attention to Afib, the most common heart rhythm disorder, which can lead to blood clots, stroke, and heart failure if left untreated. Common symptoms include palpitations, fatigue, and shortness of breath, though some people have no symptoms at all.
Ablation, particularly pulmonary vein isolation (PVI), is a well-established treatment for Afib. It is now considered first-line therapy for paroxysmal Afib, where normal rhythm returns within a week, and is increasingly used before antiarrhythmic drugs for persistent cases. The procedure typically involves minimally invasive catheterization in an electrophysiology lab to isolate abnormal electrical pathways.
Recent years have brought new technologies, including pulsed field ablation (PFA), which the FDA first approved for Afib in 2023. PFA uses high-voltage electrical fields to damage cell membranes, potentially reducing collateral damage compared with thermal methods like radiofrequency or cryoablation. A randomized trial this year found PFA as first-line treatment reduced recurrence of atrial arrhythmia in persistent Afib patients, a group that has historically had worse outcomes. However, real-world data have raised concerns about early PFA cases showing markers of non-target injury, though newer device designs are expected to mitigate these risks.